The acquisition of the beauty and biomedical division of Modern Meadow strengthens HTL's position as a global leader in the production and development of pharmaceutical-grade biopolymers.
Within a world-class scientific research center, the company integrates a team with its cutting-edge expertise in the field.
HTL Biotechnology makes a notable entry into the world of medical and cosmetic uses with their use of recombinant human collagen.
With high demand set to surpass the billion-dollar mark soon, the rhCOL3 holds significant promise and has already raised the interest of numerous players in the cosmetic and aesthetic industry.
Through this acquisition, HTL Biotechnology wants to drive innovation in the company's historical segments, including aesthetic medicine, rheumatology, and ophthalmology, as well as explore new therapeutic areas.
HTL Biotechnology will now offer a broad and distinctive range of products through its platform, including pharmaceutical-grade hyaluronic acid, polynucleotides, and products in development such as heparosan or botulinum toxin as a neuromodulator.
On the one hand, the teams from HTL Biotechnology Manufacturing Inc. are based in Massachusetts, and on the other hand, a new organization is based in New Jersey.
Franois Fournier states that he is thrilled with the commercialization of this new vegan biopolymer and the prospects that this acquisition gives him to innovate even further.
The Chairman of HTL Biotechnology says that the acquisition will accelerate the development of the company.
These biopolymers are used by healthcare companies for the development of treatments in a variety of leading therapeutic areas.
To learn more about HTL, please visit: http://htlbiotech.com/
HTL Biotechnology has a professional network.
Olivier Clement and Nathalie Chevallon are both protected by email.
There is a logo for HtL Biotechnology.
HTL was the source of the information.

Source prnewswire